Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16329564 | 1.00 | CRBN (0.33) | CRBNCA12CA1CA2CA4 | |
| SCHEMBL24297494 | 0.93 | — | — | |
| SCHEMBL24297070 | 0.93 | — | — | |
| SCHEMBL19437438 | 0.90 | CRBN (0.37) | CRBNCA12CA1CA2CA4 | |
| SCHEMBL24620135 | 0.89 | CRBN (0.34) | CRBN | |
| SCHEMBL29077934 | 0.89 | CRBN (0.34) | CRBN | |
| SCHEMBL24297230 | 0.89 | CA2 (0.36) | CA12CA1CA2CA4CA9 | |
| Trifluoroacetic Acid SCHEMBL29406774 | 0.85 | CD40 (0.34) | — | |
| SCHEMBL24297334 | 0.84 | PLK1 (0.34) | CRBNCA12CA1CA2CA9 | |
| SCHEMBL31103722 | 0.84 | GLP1R (0.34) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605459-B2 | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240252661-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-01 | — | — | US | disclosed |
| EP-4406608-A2 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-118085100-A | Camptothecin analogues conjugated to glutamine residues in proteins and uses thereof | 瑞泽恩制药公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-116390771-A | Camptothecin analogues conjugated to glutamine residues in proteins and uses thereof | 瑞泽恩制药公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20220072141-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220072141-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252661-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | TGM2, QPCT, TGM3 | CRBN 1043/4885CA12 1874/4885CA1 949/4885 |
| US-20220072141-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | TGM2, QPCT, TGM3 | CRBN 1043/4885CA12 1874/4885CA1 949/4885 |
| US-12605459-B2 | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof | FOLH1, TGM2, SLC3A2 | CRBN 1700/4885CA12 1829/4885CA1 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.